Tolvaptan sodium phosphate (brand name Samtasu) is a selective small-molecule vasopressin V2 receptor antagonist developed by Otsuka Pharmaceutical Co., Ltd. It is a prodrug form of tolvaptan (7.13) with improved water solubility. The drug was approved by Japan's PMDA in March 2022 for the treatment of fluid retention in patients who have difficulty orally ingesting tolvaptan. Tolvaptan exerts its effect by inhibiting water reabsorption in the renal collecting ducts, thereby promoting aquaresis without depleting electrolytes. It is effective in the management of heart failure patients and has demonstrated clinical benefits including weight reduction and alleviation of dyspnea and other symptoms of fluid overload. Tolvaptan is also effective in the treatment of early acute heart failure, where intravenous administration can rapidly induce aquaresis in the initial phase.